Investment
Features
FeesSafety
Academy
More
Pluang+

Compare i-80 Gold Corp. Common Shares (IAUX) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

i-80 Gold Corp. Common SharesTrade
Zimmer Biomet Holdings IncTrade

Price performance (Past 24H)

Key statistics

i-80 Gold Corp. Common Shares vs Zimmer Biomet Holdings Inc — how do they compare? i-80 Gold Corp. Common Shares trades at $1.48 (market cap $1.34B), while Zimmer Biomet Holdings Inc trades at $92.24 (market cap $17.56B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 13.1× i-80 Gold Corp. Common Shares's market cap, and Zimmer Biomet Holdings Inc pays a 1.04% dividend while i-80 Gold Corp. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold i-80 Gold Corp. Common Shares for 0 Days and Zimmer Biomet Holdings Inc for 89 Days on average.

IAUXZBH
Market Cap
$1.34B$17.56B
Volume
3,239,7252,298,426
Sector
Basic MaterialsHealth
52-Week High
$2.08$103.98
52-Week Low
$0.89$79.58
Typical Hold Time
0 Days89 Days
Enterprise Value
$1.32B$24.63B
Dividend Yield
—1.04%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

i-80 Gold Corp. Common Shares

IAUX trades at $1.54, down 2.53% today, with a neutral technical signal. The company shows significant financial challenges with a -198.82% net income margin and negative ROE of -71.66%, though revenue grew from $95M in 2025 to $130M in 2026. Recent positive developments include CEO purchasing 1 million shares and feasibility studies showing strong potential for Nevada gold projects. Analyst consensus remains unanimously bullish with 3 buy ratings.

While facing substantial profitability challenges, IAUX's development pipeline and CEO confidence suggest long-term potential. Key risks include persistent negative cash flow from operations and high debt levels. The stock presents a high-risk, high-reward opportunity dependent on successful project execution and gold price stability.

Zimmer Biomet Holdings Inc

Zimmer Biomet (ZBH) trades at $91.77, down 0.43% on the day, with a bullish technical signal supported by moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady at $8.23B for 2025, though net income margins have moderated from 13.84% in 2023 to 8.56% in 2025. The company maintains strong profitability with a 69.87% gross margin and recently announced a $0.24 quarterly dividend.

ZBH presents a mixed outlook with positive earnings momentum and analyst consensus price target of $103.11 offering 12% upside potential. However, rising debt levels and competitive pressures in medical technology pose risks. Institutional ownership trends show continued interest, with State Street increasing its position by 0.6% in Q3 2026. The stock's valuation at 22.35 P/E appears reasonable given the company's market leadership position.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

IAUX
100% Buy0% Sell
Avg holding period · 0 Days
ZBH

No sentiment data available yet.

Top news

Latest headlines on both assets

About i-80 Gold Corp. Common Shares

i-80 Gold Corp. is a mining company focused on developing and operating gold and precious-metals projects in Nevada, using a hub-and-spoke model centered on a processing facility to support multiple mine sites in the state.

Read more on IAUX →

About Zimmer Biomet Holdings Inc

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.

Read more on ZBH →